Fresenius SE & Co. KGaA (FRA:FRE) has been assigned a €83.00 ($98.81) price objective by research analysts at Deutsche Bank in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. Deutsche Bank’s price objective indicates a potential upside of 36.99% from the stock’s previous close.
Other equities analysts have also issued research reports about the company. Commerzbank set a €85.00 ($101.19) price target on Fresenius SE & Co. KGaA and gave the company a “buy” rating in a research note on Monday, November 6th. Kepler Capital Markets set a €77.00 ($91.67) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Thursday, November 2nd. Bank of America set a €75.00 ($89.29) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Monday, November 6th. Oddo Bhf set a €82.00 ($97.62) price target on shares of Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a research report on Friday, November 3rd. Finally, Goldman Sachs Group set a €78.00 ($92.86) price objective on Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a research report on Thursday, October 5th. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of €79.48 ($94.61).
Shares of Fresenius SE & Co. KGaA (FRA FRE) opened at €60.59 ($72.13) on Friday. Fresenius SE & Co. KGaA has a fifty-two week low of €60.56 ($72.10) and a fifty-two week high of €80.00 ($95.24).
COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/deutsche-bank-analysts-give-fresenius-se-83-00-price-target.html.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.